GENE ONLINE|News &
Opinion
Blog

Amgen
Amgen Faces Class Action Lawsuit for Concealing $10.7 Billion Tax Bill to Manipulate Stock Price
2023-03-16
Amgen’s Humira Biosimilar Now Available in the U.S.
2023-02-01
Following Amgen, Hummingbird Jumps Onto Synaffix’s ADC Platform In $150 Million Licensing Deal
2023-01-06
GeneOnline’s Pick: Top 10 M&A Deals in 2022
2022-12-28
Amgen Leads the Pack After Sanofi Drops Out of Horizon Bid
2022-12-11
Supreme Court Rejects Juno, Welcomes Amgen Back to Patent Discussions
2022-11-08
Amgen Lays Down $3.7 Billion For ChemoCentryx and its Autoimmune Portfolio
2022-08-04
Amgen Out-Licenses Two Therapies to Fosun Pharma to Expand Presence in China
2022-06-28
Recounting 25 Years of Genetic and Human Diversity Discovery With deCODE Founder Kari Stefansson
2022-05-26
Plexium Bags $102 Million for Targeted Protein Degraders
2022-02-24
JPM22 Highlights: Amgen Sees Potential in Arrakis, Freenome Gets Boosted by Roche Again
2022-01-12
Amgen Taps Generate to Discover Multi-Target Protein Drugs in $1.9+ Billion Deal
2022-01-07
Amgen Announces Encouraging Full Data for Migraine Drug, Aimovig
2021-11-09
Kyowa Kirin, Amgen’s Atopic Dermatitis Drug Delivers Strong Results in Phase 2 Trial
2021-10-05
NHS to Roll Out Revolutionary Lung Cancer Drug Targeting the Once ‘Undruggable’ KRAS
2021-09-12
1 2 3
LATEST
35% Of Better Therapeutics’ Staff to be Cut to Extend the Company’s Runway
2023-03-27
Pharming’s Joenja Racks Up FDA Approval For Rare Primary Immunodeficiency
2023-03-27
Ways to Reduce Carbon Emission in Cement Manufacturing
2023-03-26
Moderna Injects $76 Million To Kickstart Lipid Nanoparticle Delivery Partnership With Generation Bio
2023-03-24
Shining a Light on Oncology with Rakuten Medical Co-CEO Takashi Toraishi
2023-03-23
Incyte’s Zynyz Secures FDA Approval for Treating a Rare and Aggressive Skin Cancer
2023-03-23
Biohaven Licenses TYK2/JAK1 Dual Inhibitor From China’s Highlight In $970 Million Pact
2023-03-23
Scroll to Top